Ruth Plummer

13.7k total citations
230 papers, 6.0k citations indexed

About

Ruth Plummer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruth Plummer has authored 230 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Oncology, 94 papers in Molecular Biology and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruth Plummer's work include PARP inhibition in cancer therapy (56 papers), DNA Repair Mechanisms (34 papers) and Colorectal Cancer Treatments and Studies (33 papers). Ruth Plummer is often cited by papers focused on PARP inhibition in cancer therapy (56 papers), DNA Repair Mechanisms (34 papers) and Colorectal Cancer Treatments and Studies (33 papers). Ruth Plummer collaborates with scholars based in United Kingdom, United States and France. Ruth Plummer's co-authors include Hilary Calvert, Mark R. Middleton, Alan V. Boddy, Timothy A. Yap, Johann S. de Bono, Richard H. Wilson, Yvette Drew, Nicola J. Curtin, Wolfgang Wick and Jann N. Sarkaria and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ruth Plummer

219 papers receiving 5.9k citations

Peers

Countries citing papers authored by Ruth Plummer

Since Specialization

Citations

This map shows the geographic impact of Ruth Plummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Plummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Plummer more than expected).

Fields of papers citing papers by Ruth Plummer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Plummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Plummer. The network helps show where Ruth Plummer may publish in the future.

Co-authorship network of co-authors of Ruth Plummer

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Plummer. A scholar is included among the top collaborators of Ruth Plummer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Plummer. Ruth Plummer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study 2025 ·British Journal of Cancer ·Timothy A. Yap, Patricia LoRusso, Rowan Miller, Rebecca Kristeleit, Amanda G. Paulovich, Stephen McMorn, Lenka Oplustil O’Connor, (unknown), Paola Marco‐Casanova, Eric T. Gangl, Bharat Patel, Mark J. O’Connor, Emma Dean, (unknown), Ruth Plummer	2
2	A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers 2025 ·npj Digital Medicine ·Tom W. Andrew, (unknown), Ruth Plummer, Nick J. Reynolds, (unknown), Isaac Brownell, Penny E. Lovat, (unknown), Sophia Z. Shalhout	0
3	Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) 2024 ·JNCI Journal of the National Cancer Institute ·Elisa Fontana, Ezra Y. Rosen, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stéphanie Lheureux, Benedito A. Carneiro, Gregory M. Coté, Louise Carter, Ruth Plummer, Devalingam Mahalingam, Adrian J. Fretland, Joseph D. Schonhoft, Ian M. Silverman, Marisa J. Wainszelbaum, Yi Xu, Danielle Ulanet, María Koehler, Timothy A. Yap	7
4	First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors 2024 ·Clinical Cancer Research ·Timothy A. Yap, Anthony W. Tolcher, Ruth Plummer, Jatinder Kaur Mukker, (unknown), Christine Hicking, Thomas Grombacher, (unknown), Zoltán Szűcs, Ioannis Gounaris, Johann S. de Bono	20
5	A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma 2023 ·British Journal of Cancer ·Juanita Lopez, Julia Lai‐Kwon, R. Molife, Liam Welsh, Nina Tunariu, Desamparados Roda, (unknown), Victoria Lladó, Adrián G. McNicholl, Catalina Ana Rosselló, Richard Taylor, Analía Azaro, Jordi Rodón, Julieann Sludden, Gareth J. Veal, Ruth Plummer, Ander Urruticoechea, (unknown), (unknown), Pablo V. Escribá	10
6	Histology independent drug development – Is this the future for cancer drugs? 2023 ·Cancer Treatment Reviews ·Lucinda Billingham, (unknown), Theodor Framke, Alastair Greystoke, Eivind Hovig, (unknown), Philippe Page, (unknown), Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander, Ruth Plummer	1
7	Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib 2023 ·Clinical Cancer Research ·Ezra Y. Rosen, Timothy A. Yap, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stéphanie Lheureux, Benedito A. Carneiro, Ruth Plummer, Adrian J. Fretland, Danielle Ulanet, (unknown), Robin McDougall, María Koehler, Elisa Fontana	4
8	622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·David J. Pinato, Ruth Plummer, Martin Gutierrez, Jeffrey Yachnin, (unknown), Martin Højgaard, Knut B. Smeland, William J. Edenfield, Hans Prenen, Lars Ny, Alan Anthoney, Nuria Kotecki, Stefan N. Symeonides, Louis Viviers, (unknown), (unknown), Udai Banerji	3
9	A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours 2022 ·British Journal of Cancer ·Aya El Helali, Ruth Plummer, Gordon C. Jayson, Vicky M. Coyle, Yvette Drew, (unknown), (unknown), Andrew R. Clamp, (unknown), Helen Swaisland, Richard D. Kennedy, Aaron Cranston, Richard H. Wilson	9
10	A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer 2022 ·Clinical Cancer Research ·Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Hendrik‐Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah P. Blagden, Alan Anthoney, Barbara Klencke, Mark Kowalski, Udai Banerji	27
11	BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature 2019 ·International Journal of Gynecological Pathology ·(unknown), (unknown), Ali Kucukmetin, Nicola Cresti, Ruth Plummer, Angela Ralte, R O’Donnell	7
12	Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis 2016 ·Melanoma Research ·John T. Lear, (unknown), Ralf Gutzmer, Michael R. Migden, Ragini R. Kudchadkar, Katie Lewis, L. Dirix, Ruth Plummer, Alexander Stratigos, Anne Lynn S. Chang, Uwe Trefzer, Carmen Loquai, Martin Kaatz, P. Combemale, Manisha Mone, Henry Castro, Tingting Yi, Dalila Sellami, Reinhard Dummer	1
13	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study 2014 ·Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, (unknown), Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	14
14	Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer 2014 ·Clinical Cancer Research ·Alistair Ring, Duncan Wheatley, Helen Hatcher, Robert Laing, Ruth Plummer, Martina Uttenreuther‐Fischer, Graham Temple, (unknown), David Schnell	16
15	A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors 2014 ·Molecular Cancer Therapeutics ·Kari Kendra, Ruth Plummer, Ravi Salgia, Mary O’Brien, Elaine Paul, (unknown), Natalie Compton, Chun‐Fang Xu, Lone H. Ottesen, Miguel A. Villalona‐Calero	28
16	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, (unknown), Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji	97
17	A phase 1 study of oral rucaparib in combination with carboplatin 2013 ·European Journal of Cancer ·Patricia Roxburgh, L Rhoda Molife, Anubha Gupta, (unknown), T. R. J. Evans, Nicola Cresti, Heidi Giordano, (unknown), Sarah Jaw‐Tsai, Ruth Plummer	2
18	Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors. 2013 ·Molecular Cancer Therapeutics ·Geoffrey I. Shapiro, (unknown), Mark R. Middleton, Howard A. Burris, L Rhoda Molife, (unknown), Ryann Wilson, P. LoRusso, James Spicer, V. Diéras, Maulik Patel, (unknown), (unknown), Heidi Giordano, Ann Allen, Sarah Jaw‐Tsai, Ruth Plummer	3
19	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers 2007 ·Clinical Cancer Research ·Ruth Plummer, Gerhardt Attard, Simon Pacey, (unknown), Albiruni R. Abdul Razak, Rebecca M. Perrett, Mary Barrett, Ian Judson, Stan B. Kaye, Norma Lynn Fox, Wendy Halpern, A. Corey, Hilary Calvert, Johann S. de Bono	198
20	Phase I trial of ZD9331 given as a 30 minute infusion on days 1 and 8 with cycles repeated every 3 weeks 1998 ·UCL Discovery (University College London) ·(unknown), Philip Beale, Ruth Plummer, Martin Highley, (unknown), I. Judson, Rhodri Smith, Michael G. Hutchison, Steven D. Averbuch, Kaitlin J. Mayne	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact